Todays Report: The Astrazeneca PLC (AZN) Receives Hold Rating from Leerink Swann

The Astrazeneca PLC (AZN) Receives Hold Rating from Leerink Swann

Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating restated by investment analysts at Leerink Swann in a research note issued to investors on Sunday. They currently have a $35.00 price objective on the stock. Leerink Swann’s target price indicates a potential upside of 8.39% from the company’s previous close.

Several other research firms also recently weighed in on AZN. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Shore Capital reissued a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Argus initiated coverage on Astrazeneca PLC in a research report on Tuesday, July 12th. They set a “hold” rating on the stock. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Finally, TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.56.

Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The stock has a market cap of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. The firm’s 50-day moving average price is $33.23 and its 200 day moving average price is $30.79.

10/09/astrazeneca-plc-azn-receives-hold-rating-from-leerink-swann.html

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.21 EPS. On average, analysts anticipate that Astrazeneca PLC will post $2.97 earnings per share for the current year.

The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were paid a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 78.29%.

A number of large investors have recently added to or reduced their stakes in the stock. Veritable L.P. boosted its stake in Astrazeneca PLC by 0.5% in the second quarter. Veritable L.P. now owns 9,972 shares of the company’s stock worth $301,000 after buying an additional 54 shares during the period. Fifth Third Bancorp boosted its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the period. Logan Capital Management Inc. raised its position in shares of Astrazeneca PLC by 0.6% in the first quarter. Logan Capital Management Inc. now owns 19,698 shares of the company’s stock worth $554,000 after buying an additional 109 shares in the last quarter. Independent Portfolio Consultants Inc. raised its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Independent Portfolio Consultants Inc. now owns 22,720 shares of the company’s stock worth $738,000 after buying an additional 145 shares in the last quarter. Finally, National Planning Corp raised its position in shares of Astrazeneca PLC by 1.0% in the second quarter. National Planning Corp now owns 17,742 shares of the company’s stock worth $607,000 after buying an additional 175 shares in the last quarter. Institutional investors own 11.39% of the company’s stock.

About Astrazeneca PLC

Related posts

Leave a Comment